Read by QxMD icon Read

deb-tace hcc

Andrew J Gunn, Rahul A Sheth, Brandon Luber, Minh-Huy Huynh, Niranjan R Rachamreddy, Sanjeeva P Kalva
PURPOSE: The purpse of this study was to evaluate the ability of various radiologic response criteria to predict patient outcomes after trans-arterial chemo-embolization with drug-eluting beads (DEB-TACE) in patients with advanced-stage (BCLC C) hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Hospital records from 2005 to 2011 were retrospectively reviewed. Non-infiltrative lesions were measured at baseline and on follow-up scans after DEB-TACE according to various common radiologic response criteria, including guidelines of the World Health Organization (WHO), Response Evaluation Criteria in Solid Tumors (RECIST), the European Association for the Study of the Liver (EASL), and modified RECIST (mRECIST)...
January 2017: Cardiovascular and Interventional Radiology
Stephen P Reis, Patrick D Sutphin, Amit G Singal, Richard Grzybowski, Stephen Fisher, Christopher Ball, Yin Xi, Simer Grewal, Sanjeeva P Kalva
PURPOSE: Treatment response to drug-eluting bead chemoembolization (DEB-TACE) is well established for patients with hepatocellular carcinoma (HCC); however, few studies have evaluated tumor imaging characteristics associated with treatment responses. The aim of our study was to identify imaging characteristics associated with treatment responses and overall survival after DEB-TACE of HCC. METHODS: This is a retrospective cohort study of 33 tumors in 32 patients who underwent DEB-TACE for inoperable HCC in a single, large academic medical center...
November 7, 2016: Journal of Computer Assisted Tomography
Alvin Ho-Kwan Cheung, Colin Siu-Chi Lam, Henry Shiu-Cheung Tam, Tan-To Cheung, Roberta Pang, Ronnie Tung-Ping Poon
BACKGROUND: Chemoembolization with doxorubucin-eluting beads (DEB) has been used to treat hepatocellular carcinoma (HCC) since 2007. This study compared the efficacy and survival between transarterial chemoembolization (TACE) with DEB and conventional approach (cTACE) in HCC treatment. METHODS: This retrospective case-control study compared the overall survival and tumor response of HCC patients to cTACE (n=190) and DEB (n=143) by the reassessment of computed tomography and serum alpha-fetoprotein (AFP)...
October 2016: Hepatobiliary & Pancreatic Diseases International: HBPD INT
Ran Tao, Xiaodan Li, Ruizhi Ran, Zhihua Xiao, Hongyue Zhang, Hongyan Kong, Qiqin Song, Yu Huang, Likui Wang, Jiaquan Huang
Hepatocellular carcinoma (HCC) is usually managed by the transcatheter arterial chemoembolization (TACE). However, this technique has been challenged since severe complications have been observed in clinical practices. As a result, clinicians have started to seek other minimally invasive surgeries with equivalent efficacy. The corresponding surgeries were assessed by the five outcomes: complete response (CR), partial response (PR), stable disease (SD), progression disease (PD) and objective response rate (ORR)...
September 29, 2016: Oncotarget
F Abdul Rahman, J Naidu, C S Ngiu, Y Yaakob, Z Mohamed, H Othman, R Jarmin, M H Elias, N Abdul Hamid, N Mohd Mokhtar, Ra Raja Ali
BACKGROUND: Hepatocellular carcinoma (HCC) is a common cancer that is frequently diagnosed at an advanced stage. Transarterial chemoembolisation (TACE) is an effective palliative treatment for patients who are not eligible for curative treatment. The two main methods for performing TACE are conventional (c-TACE) or with drug eluting beads (DEB-TACE). We sought to compare survival rates and tumour response between patients undergoing c-TACE and DEB-TACE at our centre. MATERIALS AND METHODS: A retrospective cohort study of patients undergoing either treatment was carried out from January 2009 to December 2014...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Nils Rathmann, Maliha Sadick, Bjoern Rathmann, Michael Kostrzewa, Christel Weiss, Stefan O Schoenberg, Steffen J Diehl, Christoph Antoni
AIM: To evaluate drug-eluting beads (DEB) for transarterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) A to D suffering from hepatocellular carcinoma. MATERIAL AND METHODS: The progression-free interval (PFI), survival and laboratory findings of 46 patients were retrospectively analyzed after DEB TACE. RESULTS: The mean survival interval was 16.93 months. The BCLC A/B group had significantly (p=0.01) longer survival compared to C/D: 20...
September 2016: In Vivo
Johannes M Ludwig, Di Zhang, Minzhi Xing, Hyun S Kim
OBJECTIVE: To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ((90)Y)-radioembolization for hepatocellular carcinoma (HCC). METHODS: Studies comparing conventional (c)TACE versus (90)Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus (90)Y-radioembolization was used...
August 25, 2016: European Radiology
Yong Kang Lee, Kyu Sik Jung, Do Young Kim, Jin Young Choi, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Kwang-Hyub Han, Gyoung Min Kim, Man Deuk Kim, Sung Il Park, Jong Yun Won, Do Yun Lee
BACKGROUND & AIMS: To evaluate clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent trans-arterial chemoembolization (TACE) using drug-eluting beads (DEB). PATIENTS AND METHODS: We retrospectively compared the clinical outcomes of 250 consecutive patients who underwent DEB-TACE (n = 106) or conventional TACE (cTACE) (n = 144) in a tertiary center between January 2010 and April 2014. The median age of the patients was 62 years and 81...
August 9, 2016: Journal of Gastroenterology and Hepatology
Arnaud Monier, Boris Guiu, Rafael Duran, Serge Aho, Pierre Bize, Pierre Deltenre, Vincent Dunet, Alban Denys
OBJECTIVES: To compare transarterial chemoembolization (TACE)-related hepatic toxicities of conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE) in patients with intermediate-stage hepatocellular carcinoma. METHODS: In this retrospective study, 151 consecutive patients undergoing cTACE or DEB-TACE and MRI 3-6 weeks before and after therapy were included. Toxicity was assessed on imaging (global hepatic damages (GHD), overall biliary injuries, biliary cast, bile duct dilatation, intrahepatic biloma, portal thrombosis), and clinico-biological follow-ups...
July 19, 2016: European Radiology
Jing Huai Zou, Lan Zhang, Zheng Gang Ren, Sheng Long Ye
OBJECTIVE: Conflicting results of the efficacy and safety of conventional transarterial chemo-embolization (cTACE) vs drug-eluting bead (DEB)-TACE have been reported. This meta-analysis aimed to update and re-evaluate the efficacy and safety of cTACE compared with those of DEB-TACE in patients with hepatocellular carcinoma (HCC). METHODS: Literature search was performed by two investigators independently in PubMed, MEDLINE and EMBASE to screen studies published from January 1990 to March 2015...
August 2016: Journal of Digestive Diseases
Johannes Baur, Christian O Ritter, Christoph-Thomas Germer, Ingo Klein, Ralph Kickuth, Ulrich Steger
PURPOSE: In hepatocellular carcinoma patients with large or multinodal tumors, where curative treatment options are not feasible, transarterial therapies play a major role. Transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) is a promising new approach due to higher intratumoral and lower systemic concentration of the chemotherapeutic agent compared to conventional TACE (cTACE). PATIENTS AND METHODS: In a retrospective analysis, 32 patients with hepatocellular carcinoma who received either DEB or a cTACE were compared regarding survival time, disease recurrence, and side effects such as pain and fever...
2016: Hepatic Medicine: Evidence and Research
Peng Chen, Peng Yuan, Bo Chen, Jingchang Sun, Hang Shen, Yeben Qian
BACKGROUND AND OBJECTIVES: Transcatheter arterial chemoembolization (TACE) is the first-line treatment for unresectable hepatocellular carcinoma (HCC). It consists of conventional TACE (cTACE) and drug-eluting beads TACE (DEB-TACE). The comparative outcomes of the two methods remain controversial. The study aim to research the optimal TACE strategy for unresectable HCC. METHODS: A systematic search of keywords, including 'HCC' and 'drug-eluting beads' was performed including four electronic databases: PubMed, Embase, China Biological Medicine Database (CBM), and Cochrane library databases from the date of inception to December 25, 2015...
June 24, 2016: Clinics and Research in Hepatology and Gastroenterology
Boris Gorodetski, Julius Chapiro, Ruediger Schernthaner, Rafael Duran, MingDe Lin, Howard Lee, David Lenis, Elizabeth A Stuart, Bareng Aletta Sanny Nonyane, Vasily Pekurovsky, Anobel Tamrazi, Bernhard Gebauer, Todd Schlachter, Timothy M Pawlik, Jean-Francois Geschwind
OBJECTIVES: Our study sought to compare the overall survival in patients with hepatocellular carcinoma (HCC) and portal venous thrombosis (PVT), treated with either conventional trans-arterial chemoembolization (cTACE) or drug-eluting beads (DEB) TACE. METHODS: This retrospective analysis included a total of 133 patients, treated without cross-over and compared head-to-head by means or propensity score weighting. Mortality was compared using survival analysis upon propensity score weighting...
February 2017: European Radiology
Raj Vasnani, Michael Ginsburg, Osman Ahmed, Taral Doshi, John Hart, Helen Te, Thuong Gustav Van Ha
BACKGROUND: Bridging therapy plays an increasingly important role in the management of patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). Combination therapy with drug-eluting bead transarterial chemoembolization (DEB-TACE) and percutaneous thermal ablation, such as radiofrequency ablation (RFA) or microwave ablation (MWA), has shown success at prolonging survival and bridging patients to LT. However, few studies have evaluated the two combination therapy regimens head-to-head at a single institution, and fewer have compared histopathology...
June 2016: Hepatobiliary Surgery and Nutrition
Atsuyuki Ikeda, Yumiko Yasuhara, Daizen Hirata, Mari Teramura, Takeharu Nakamura, Yoko Oiwa, Osamu Araki, Hidemasa Azechi, Ryuta Nishitai, Hiroyuki Kokuryu
We report a case of resected hepatocellular carcinomas (HCCs) after drug-eluting bead transarterial chemoembolization (DEB-TACE). A 67-year-old man with alcoholic liver disease was diagnosed with HCCs. Serological markers for hepatitis B and C viruses were negative. Among tumor markers, alpha-fetoprotein was 2.7ng/mL, and protein induced by vitamin K absence II was 868mAU/mL. Two HCCs were detected using dynamic computed tomography: one was 9cm in diameter in S8 and the other was 2cm in diameter in S4. We performed DEB-TACE using HepaSphere(®) and epirubicin...
2016: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
Alessandro Cucchetti, Franco Trevisani, Alberta Cappelli, Cristina Mosconi, Matteo Renzulli, Antonio Daniele Pinna, Rita Golfieri
BACKGROUND: Doxorubicin-loaded drug-eluting beads TACE (DEB-TACE) has been developed to maximize the therapeutic efficacy of conventional trans-catheter arterial chemo-embolization (cTACE) in patients with hepatocellular carcinoma (HCC); however, its cost-effectiveness (CE) still needs to be assessed. AIMS: To investigate the CE of DEB-TACE versus cTACE. METHODS: Results from a meta-analysis of the pertinent literature were used to construct a CE Markov simulation model which followed a hypothetical cohort of HCC patients who underwent DEB-TACE or cTACE, covering the entire post-TACE lifespan until death...
July 2016: Digestive and Liver Disease
Seungsoo Lee, Kyoung Min Kim, Shin Jae Lee, Kwang-Hun Lee, Do Yun Lee, Man Deuk Kim, Do Young Kim, Seung Up Kim, Jong Yun Won
BACKGROUND: Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) frequently causes feeding artery stenosis or occlusion that may interfere with repeated treatment. PURPOSE: To investigate the incidence and predictors of hepatic arterial damage (HAD) after drug-eluting bead-TACE (DEB-TACE) in comparison with conventional TACE (Conv-TACE). MATERIAL AND METHODS: We retrospectively analyzed 54 patients who underwent DEB-TACE for HCC as an initial treatment with follow-up angiography and 54 patients who underwent Conv-TACE using doxorubicin-lipiodol mixture and gelfoam particles for comparison...
May 22, 2016: Acta Radiologica
Rita Y W Chiu, Wan W Yap, Roshni Patel, David Liu, Darren Klass, Alison C Harris
Embolotherapies used in the treatment of hepatocellular carcinoma (HCC) include bland embolization, conventional transarterial chemoembolization (cTACE) using ethiodol as a carrier, TACE with drug-eluting beads and super absorbent polymer microspheres (DEB-TACE), and selective internal radiation therapy (SIRT). Successfully treated HCC lesions undergo coagulation necrosis, and appear as nonenhancing hypoattenuating or hypointense lesions in the embolized region on computed tomography (CT) and magnetic resonance...
May 2016: Canadian Association of Radiologists Journal, Journal L'Association Canadienne des Radiologistes
Minzhi Xing, Nima Kokabi, Hasmukh J Prajapati, Orrie Close, Johannes M Ludwig, Hyun S Kim
AIM: To evaluate overall survival (OS) in unresectable American Joint Committee on Cancer (AJCC) stage I/II hepatocellular carcinoma (HCC) treated with drug-eluting-bead transarterial chemoembolization (DEB-TACE) versus best supportive care. MATERIALS & METHODS: OS in consecutive patients with AJCC stage I/II unresectable HCC diagnosed in 2005-2010 who underwent DEB-TACE and similar patients from SEER with no surgery/radiation recommended/performed was evaluated...
March 2016: Journal of Comparative Effectiveness Research
Yang Hui, Tang Ruihua, Li Jing, Liu Yaxiong, Li Ji, Ye Linjie, Shao Dongyan, Jin Mingliang, Huang Qingsheng, Shi Junling
BACKGROUND/AIMS: To evaluate the efficacy and safety of doxorubicin-eluting beads combined with transcatheter arterial chemoembolization (DEB-TACE) compared with conventional TACE (cTACE). METHODOLOGY: PubMed, EMBASE, MEDLINE and Cochrane Controlled Trials Register were searched for articles published to identify randomized controlled trials evaluating efficacy and side effects between DEB-TACE and cTACE. The RR (relative risk) with a 95% confidence interval (CI) was calculated by the Revman 5...
June 2015: Hepato-gastroenterology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"